OSTX

OS Therapies Inc

Jul 16 • 04:00PM ET

1.68

Dollar change +0.10
Percentage change 6.33	%

Healthcare • Biotechnology • USA • AMEX

Peers: MRK PFE JNJ AMGN BMY GILD LLY REGN BIIB VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	43.77%	Shs Outstand	21.35M	Perf Week	1.20%
Market Cap	47.21M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	-2.06%	Shs Float	15.80M	Perf Month	-7.69%
Enterprise Value	49.04M	PEG	-	EPS next Q	-0.12	Inst Own	1.39%	Short Float	2.18%	Perf Quarter	28.24%
Income	-13.27M	P/S	-	EPS this Y	149.15%	Inst Trans	207.80%	Short Ratio	0.72	Perf Half Y	-63.87%
Sales	0.00M	P/B	-	EPS next Y	-131.21%	ROA	-426.54%	Short Interest	0.34M	Perf YTD	-60.75%
Book/sh	-0.20	P/C	15.89	EPS next 5Y	-	ROE	-	52W High	7.00 -76.00%	Perf Year	-
Cash/sh	0.11	P/FCF	-	EPS past 3/5Y	88.31% 79.38%	ROIC	-2162.87%	52W Low	1.12 50.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.24% 7.74%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-75.62%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.16	EPS Q/Q	-159.09%	SMA20	-3.92%	Beta	-	Target Price	13.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-4.14%	Rel Volume	0.61	Prev Close	1.58
Employees	4	LT Debt/Eq	0.00	Earnings	May 16 BMO	SMA200	-26.98%	Avg Volume	478.51K	Price	1.68
IPO	Aug 01, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-109.55% -	Trades		Volume	294,727	Change	6.33%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Initiated	Lake Street	Buy	$19

Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +6.33%
Jul-14-25 07:40AM	OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer (Newsfile) -8.24%
Jul-10-25 07:40AM	OS Therapies Provides Clinical & Global Regulatory Updates (Newsfile)
Jul-03-25 07:40AM	OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (Business Wire)
Jun-30-25 06:00AM	OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference (Business Wire)
11:44AM	Loading…
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 07:40AM	OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma (Business Wire)
Jun-23-25 08:29PM	OS Therapies Announces Warrant Exercise Inducement & Exchange Offer (Business Wire)
Jun-10-25 07:40AM	OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma (PR Newswire)
Jun-06-25 07:30AM	OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma (Business Wire)
May-16-25 06:00AM	OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-15-25 06:00AM	OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma (Business Wire) -7.78%
May-07-25 08:45AM	OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040 (Business Wire) -21.37%
May-02-25 09:32AM	Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies (Business Wire) +5.70%
Apr-22-25 07:40AM	OS Therapies FDA Meeting Request Granted (Business Wire)
10:15AM	Loading…
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire)
Apr-10-25 07:42AM	OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans (Business Wire) -16.42%
Apr-09-25 07:40AM	OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals (Business Wire)
Apr-07-25 06:00AM	OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma (Business Wire)
Apr-02-25 07:40AM	OS Therapies to Host Analyst Day at NYSE on April 7, 2025 (Business Wire) +13.53%
Mar-31-25 04:30PM	OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire) -13.64%
07:40AM	OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma (Business Wire)
Mar-25-25 07:40AM	OS Therapies OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers (Business Wire) -5.36%
Mar-23-25 08:49AM	OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-21-25 07:40AM	OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference (Business Wire) +8.81%
Mar-13-25 07:40AM	OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference (Business Wire)
Mar-11-25 07:40AM	OS Therapies Schedules United Kingdoms Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma (Business Wire)
Feb-28-25 09:00AM	Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Feb-26-25 04:01PM	Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on February 27 (Business Wire)
Feb-24-25 07:25AM	OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms (Business Wire)
05:00AM	Loading…
Feb-20-25 05:00AM	OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2 (Business Wire)
Feb-14-25 01:51PM	Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer (Benzinga) +12.06%
07:36AM	OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing (Business Wire)
Feb-04-25 07:33AM	OS Therapies Provides Corporate Update (Business Wire) +10.29%
Feb-03-25 08:30AM	RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis (ACCESS Newswire)
Jan-30-25 09:35AM	OS Therapies to acquire listeria programs from Ayala Pharmaceuticals (TipRanks) -25.00%
Jan-29-25 10:05AM	OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline (Business Wire)
Jan-17-25 08:35AM	OS Therapies price target raised to $15 from $8 at Maxim (TipRanks) -28.40%
Jan-15-25 09:17AM	OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma (Business Wire)
Jan-02-25 11:16AM	OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 03:38PM	OS Therapies Announces Closing of $6 Million Private Placement (Business Wire) -8.94%
Dec-26-24 12:04PM	OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online (NewMediaWire) +33.29%
Dec-25-24 09:40AM	OS Therapies to sell 1.5M units at $4.00 in private placement (TipRanks)
Dec-24-24 09:32AM	OS Therapies Announces Pricing of $6 Million Private Placement (Business Wire)
Nov-15-24 09:47AM	OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-04-24 07:00AM	OS Therapies to Present at The Spartan Capital Investor Conference (Business Wire)
Oct-30-24 08:51AM	Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on October 30 (Business Wire)
Oct-28-24 04:44PM	OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors (Business Wire) -8.69%
Oct-24-24 08:46AM	OS Therapies to Present at the LD Micro Main Event XVII (Business Wire)
Oct-17-24 09:22AM	OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Oct-03-24 08:00AM	OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit (Business Wire)
Sep-13-24 08:09AM	OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates (Business Wire)
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-11-24 08:15AM	OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models (ACCESSWIRE) -6.40%
Sep-05-24 08:22AM	OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference (Business Wire)
Aug-29-24 07:53AM	OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose (Business Wire)
Aug-22-24 08:00AM	OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board (Business Wire)
06:00AM	OS Therapies Clarifies CUSIP of Common Stock (Business Wire)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-19-24 08:30AM	OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS (Business Wire) +14.66%
Aug-15-24 08:30AM	OS Therapies Reports Second Quarter 2024 Financial Results (ACCESSWIRE) +12.03%
Aug-09-24 09:00AM	OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +33.78%
Aug-06-24 08:35AM	OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board (ACCESSWIRE) +17.37%
Aug-02-24 08:55AM	OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board (Business Wire) +59.36%
Jul-31-24 06:21PM	OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol "OSTX" (Business Wire)
Jul-24-24 10:48AM	OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer (Business Wire)
Jun-03-24 12:44PM	OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma (Business Wire)

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Grasonville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Auerbach Shalom	10% Owner	May 07 '25	Sale	2.00	82,000	163,918	2,664,199	May 09 09:30 PM
Einodmil LLC	10% Owner	May 07 '25	Proposed Sale	2.34	1,200,000	2,808,000		May 07 09:25 AM
Auerbach Shalom	10% Owner	Apr 09 '25	Sale	1.35	50,012	67,666	2,756,199	Apr 11 09:45 PM
Auerbach Shalom	10% Owner	Apr 10 '25	Sale	1.39	10,000	13,900	2,746,199	Apr 11 09:45 PM
Auerbach Shalom	10% Owner	Feb 14 '25	Sale	2.84	100,000	284,300	2,431,211	Feb 18 09:00 PM
Auerbach Shalom	10% Owner	Jan 15 '25	Sale	6.74	16,720	112,609	2,531,211	Jan 17 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OSTX

OS Therapies Inc

Upgrade your FINVIZ experience